BETA
Your AI-Trained Oncology Knowledge Connection!
Adagrasib/Pembrolizumab Yields Improved Survival in KRAS G12C-Mutated NSCLC
Results from the KRYSTAL-7 trial showed that efficacy was improved with adagrasib/pembrolizumab for KRAS G12C-mutated NSCLC.
Adjuvant Nivolumab Provides Sustained Benefit in Resected Esophageal/GEJ Cancer
Five-year follow-up confirms adjuvant nivolumab's sustained disease-free and distant metastasis-free survival benefits in resected esophageal/GEJ cancer post-CRT.
NAPOLI-3 Post Hoc Review Highlights Long-Term Survival With NALIRIFOX in PDAC
A post hoc analysis of NAPOLI-3 reveals clinical characteristics and treatment strategies associated with long-term survival in patients with metastatic PDAC treated with NALIRIFOX.
Fruquintinib Combo Exhibits Frontline Efficacy in Advanced ESCC
No fatalities were observed with fruquintinib plus camrelizumab, paclitaxel liposome, and nedaplatin when treating esophageal squamous cell carcinoma.
Recurrence or Risk of Death Reduced by 50% With Atezolizumab/Chemo in dMMR Colon Cancer
Results from the ATOMIC trial found a 50% reduction in the risk of death for patients with dMMR colon cancer receiving atezolizumab/chemotherapy.
Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer
Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.
Durvalumab Regimen Extends EFS in Resectable Gastric/GEJ Adenocarcinoma
Data from the MATTERHORN trial may be “practice-changing” in the management of resectable gastric or gastroesophageal junction adenocarcinoma.
Adjuvant Nivolumab/Cisplatin/RT Improves DFS in Advanced Head and Neck Cancer
Results from the NIVOPOSTOP trial found improved DFS with adjuvant nivolumab plus cisplatin and RT for patients with LA-SCCHN.
Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer
Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.
T-DXd Yields PFS Across Mutation Subtypes for HR+, HER2-low Breast Cancer
In the phase 3 DESTINY-Breast06 trial, the overall biomarker-evaluable population’s confirmed ORR was 59.4% with T-DXd vs 33.9% with chemotherapy.
Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm
Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.
Amivantamab/Chemo Sustains Efficacy Despite Osimertinib Resistance in EGFR-Mutated NSCLC
Amivantamab/chemotherapy remained efficacious regardless of the osimertinib resistance mechanism for patients with EGFR-mutated NSCLC.
Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL
After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL.
40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data
PROs Favor Imlunestrant With/Without Abemaciclib in ER+, HER2– Breast Cancer
Across all 3 treatment arms, global health status/quality of life and functional domains were maintained in the phase 3 EMBER-3 trial.
Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC
As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.
Zanubrutinib Shows Sustained Efficacy in Chronic Lymphocytic Leukemia
With longer-term follow-up, investigators observed no new safety signals for zanubrutinib in patients with CLL or SLL harboring 17p deletions.
Targeted Tool May Optimize Infusion Therapy Delivery in Breast Cancer
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Novel CAR T-Cell Therapy Yields Responses in Relapsed/Refractory Lymphoma
Treatment with KITE-363 yields no dose-limiting toxicities in a first-in-human phase 1 study.
Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo
Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.
Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC
The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.
Anlotinib Shows Noninferiority to Bevacizumab in RAS/BRAF Wild-Type mCRC
Anlotinib/chemotherapy showed comparable efficacy vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors
T-DXd rechallenge occurred after grade 1 ILD, and was proven safe for patients with breast cancer/solid tumors.
ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer
Escalated adjuvant chemotherapy did not improve recurrence-free survival in patients with stage III colon cancer when using a ctDNA-informed approach.
Sacituzumab Govitecan/Pembrolizumab Show Promise as SOC in 1st Line PD-L1+ TNBC
PFS was improved with first-line sacituzumab govitecan plus pembrolizumab for patients with PD-L1–positive metastatic TNBC.
Vepdegestrant Outperforms Fulvestrant in PFS for ESR1-Mutant Advanced Breast Cancer
Vepdegestrant shows significant clinical activity and a favorable safety profile in ESR1-mutant HER2-negative, ER-positive metastatic breast cancer vs fulvestrant.
T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer
T-DXd improved OS, PFS, ORR, and DOR vs ramucirumab plus paclitaxel in the second-line treatment of HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
Isatuximab Shows Efficacy, Acceptable Safety Across Multiple Myeloma Trials
At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists
Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma
Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.
